Clinical implications of antiretroviral drug interactions with warfarin: A case-control study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1360-1363

  Esterly, John S ^a,b   Darin, Kristin M ^b,c   Gerzenshtein, Lana ^b   Othman, Fidah ^a   Postelnick, Michael J ^b,c   Scarsi, Kimberly K ^b,c  

^a CHICAGO STATE UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticoagulation; HIV; Non nucleoside reverse transcriptase inhibitors; Protease inhibitors; Venous thromboembolism

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; WARFARIN;

ADULT; AFRICAN AMERICAN; ANTICOAGULANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MALE; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

ANTICOAGULATION; HIV; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; PROTEASE INHIBITORS; VENOUS THROMBOEMBOLISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DRUG INTERACTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84884921964     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt043     Document Type: Article

References (19)

1. Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterr J Hematol Infect Dis 2011; 3: e2011030.
2. FORBES 2011. America's Most Popular Drugs. http://www.forbes. com/sites/matthewherper/2011/04/19/americas-most-popular-drugs/ (13 December 2012, date last accessed).
3. Breckenridge A, Orme M, Wesseling H et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30.
4. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http:// aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (13 January 2013, date last accessed).
5. Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009; 43: 322-8.
6. Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 2010; 9: 215-23.
7. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31.
8. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52-60.
9. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008; 46: 146-7.
10. Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy- warfarin drug interaction. Pharmacotherapy 2008; 28: 945-9.
11. Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998; 12: 825-6.
12. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007; 177: 357-9.
13. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998; 32: 1299-302.
14. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999; 13: 1788-9.
15. Liedtke MD, Vanguri A, Rathbun RC. A probable interaction between warfarin and the antiretroviral TRIO study regimen. Ann Pharmacother 2012; 46: e34.
16. Sustiva (Package Insert). Princeton: Bristol-Myers Squibb Company, January 2013.
17. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-9.
18. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88: 676-84.
19. McIlleron H, Martinson N, Denti P, et al. Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment: the TSHEPISO Study Team. In: Abstracts of the Twenty-ninth International AIDS Conference, Washington, DC, 2012. Abstract MOAB0303. http://pag. aids2012.org/abstracts.aspx?aid=10371 (13 January 2013, date last accessed).